Many biopharmaceutical organizations are committed to reducing their carbon footprints in alignment with the United Nations Paris Agreement. However, achieving these goals without compromising safety, quality, or development timelines is no small act and will require organization-wide focus and innovative solutions implemented toward near- and long-term goals.
Modern clinical trials pose a complex and matrixed challenge for our community as we work to
lower the greenhouse gas emissions (GHG) of trials. Emissions are additive, and contributions
from many different organizations, patients, healthcare professionals, and all others matter.
We all must work together toward a common goal. Read this white paper by sustainable clinical trial expert Michael Cohen which explores:
Offered Free by: PPD
See All Resources from: PPD